Seven Fleet Capital Management LP Purchases Shares of 14,540 Amylyx Pharmaceuticals, Inc. $AMLX

Seven Fleet Capital Management LP acquired a new stake in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 14,540 shares of the company’s stock, valued at approximately $261,138,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Corient Private Wealth LP purchased a new position in shares of Amylyx Pharmaceuticals during the second quarter worth about $1,065,000. Bank of America Corp DE acquired a new position in shares of Amylyx Pharmaceuticals in the second quarter valued at approximately $14,760,000. Jupiter Topco LLC purchased a new position in Amylyx Pharmaceuticals during the 2nd quarter worth $94,014,000. Elmind Capital LP purchased a new position in Amylyx Pharmaceuticals during the 2nd quarter worth $2,011,520,000. Finally, Hsbc Holdings PLC purchased a new position in Amylyx Pharmaceuticals during the 2nd quarter worth $269,000. Institutional investors and hedge funds own 95.84% of the company’s stock.

Amylyx Pharmaceuticals Trading Down 1.0%

AMLX stock opened at $37.08 on Thursday. The firm has a 50 day moving average of $21.72 and a 200-day moving average of $17.20. Amylyx Pharmaceuticals, Inc. has a 12-month low of $8.94 and a 12-month high of $41.14. The company has a market cap of $4.13 billion, a price-to-earnings ratio of -25.93 and a beta of -0.21.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.03). Sell-side analysts forecast that Amylyx Pharmaceuticals, Inc. will post -1.48 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Amylyx Pharmaceuticals news, insider Gina Mazzariello sold 15,000 shares of the company’s stock in a transaction on Thursday, July 9th. The stock was sold at an average price of $18.32, for a total value of $274,800.00. Following the sale, the insider owned 194,090 shares of the company’s stock, valued at approximately $3,555,728.80. This represents a 7.17% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 10.90% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on AMLX. Mizuho lifted their target price on shares of Amylyx Pharmaceuticals from $30.00 to $42.00 and gave the company an “outperform” rating in a report on Tuesday, August 18th. Citigroup lifted their price objective on Amylyx Pharmaceuticals from $20.00 to $26.00 and gave the company a “buy” rating in a report on Monday, August 3rd. Weiss Ratings reissued a “sell (d-)” rating on shares of Amylyx Pharmaceuticals in a report on Wednesday, August 5th. Guggenheim lifted their price target on Amylyx Pharmaceuticals from $40.00 to $55.00 and gave the company a “buy” rating in a research note on Wednesday, August 19th. Finally, Wall Street Zen lowered Amylyx Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Two equities research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, Amylyx Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $36.25.

About Amylyx Pharmaceuticals